Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 7/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.52 |
| ▸ | CDK2 | P24941 | 7/20 | 0.52 |
| ▸ | TK1 | P04183 | 1/20 | 0.44 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.43 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7661515 | 0.96 | CCNE1 (0.54) | PDGFRACCNE1CDK2TK1TMIGD3 | |
| SCHEMBL7668440 | 0.90 | CCNE1 (0.51) | PDGFRACCNE1CDK2TK1KCNH3 | |
| SCHEMBL7363250 | 0.88 | TK1 (0.53) | PDGFRACCNE1CDK2TK1TAAR1 | |
| SCHEMBL7661378 | 0.87 | CCNE1 (0.51) | PDGFRACCNE1CDK2TK1KCNH3 | |
| SCHEMBL7668634 | 0.87 | CCNE1 (0.54) | PDGFRACCNE1CDK2TK1TMIGD3 | |
| SCHEMBL7674300 | 0.86 | CTSL (0.50) | PDGFRACCNE1CDK2 | |
| SCHEMBL7667654 | 0.86 | CCNE1 (0.53) | PDGFRACCNE1CDK2TK1KCNH3 | |
| SCHEMBL7363934 | 0.85 | CCNE1 (0.52) | PDGFRACCNE1CDK2TK1TMIGD3 | |
| SCHEMBL7358873 | 0.85 | CTSL (0.46) | PDGFRACCNE1CDK2KCNH3 | |
| SCHEMBL24021926 | 0.84 | CCNE1 (0.46) | PDGFRACCNE1CDK2TMIGD3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414147-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | claimed |
| US-6414147-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |